Literature DB >> 12010196

Angiotensin AT1 receptor signalling pathways in neurons.

Colin Sumners1, Melissa A Fleegal, Mingyan Zhu.   

Abstract

1. The aim of the present article is to review the intracellular signal transduction pathways that are influenced by the peptide angiotensin (Ang) II, acting via its type 1 (AT1) receptor, in neurons. 2. The AT1 receptors couple to a wide variety of signalling pathways in peripheral tissues, such as kidney, heart and vascular smooth muscle. A similar diversity of signalling mechanisms exists for AT1 receptors in neurons. 3. We outline the known neuronal AT1 receptor signalling pathways as they relate to function. Pathways that couple activation of AT1 receptors to short-term changes in neuronal membrane ionic currents and firing rate will be reviewed. These are different from the pathways that elicit longer-term changes in enzyme activity and gene expression and, ultimately, increases in noradrenaline synthesis. 4. Novel AT1 receptor signalling pathways discovered through gene expression profiling and their potential functional significance have been discussed.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12010196     DOI: 10.1046/j.1440-1681.2002.03660.x

Source DB:  PubMed          Journal:  Clin Exp Pharmacol Physiol        ISSN: 0305-1870            Impact factor:   2.557


  30 in total

1.  Decreased nNOS in the PVN leads to increased sympathoexcitation in chronic heart failure: role for CAPON and Ang II.

Authors:  Neeru M Sharma; Hong Zheng; Parmender P Mehta; Yi-Fan Li; Kaushik P Patel
Journal:  Cardiovasc Res       Date:  2011-08-10       Impact factor: 10.787

2.  Chronic AT1 receptor blockade normalizes NMDA-mediated changes in renal sympathetic nerve activity and NR1 expression within the PVN in rats with heart failure.

Authors:  Allison C Kleiber; Hong Zheng; Neeru M Sharma; Kaushik P Patel
Journal:  Am J Physiol Heart Circ Physiol       Date:  2010-02-19       Impact factor: 4.733

3.  Exercise training normalizes enhanced glutamate-mediated sympathetic activation from the PVN in heart failure.

Authors:  Allison C Kleiber; Hong Zheng; Harold D Schultz; Jacob D Peuler; Kaushik P Patel
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2008-04-02       Impact factor: 3.619

4.  Multiscale model of dynamic neuromodulation integrating neuropeptide-induced signaling pathway activity with membrane electrophysiology.

Authors:  Hirenkumar K Makadia; Warren D Anderson; Dirk Fey; Thomas Sauter; James S Schwaber; Rajanikanth Vadigepalli
Journal:  Biophys J       Date:  2015-01-06       Impact factor: 4.033

5.  (Pro)renin receptor knockdown in the paraventricular nucleus of the hypothalamus attenuates hypertension development and AT1 receptor-mediated calcium events.

Authors:  Lucas A C Souza; Caleb J Worker; Wencheng Li; Fatima Trebak; Trevor Watkins; Ariana Julia B Gayban; Evan Yamasaki; Silvana G Cooper; Bernard T Drumm; Yumei Feng
Journal:  Am J Physiol Heart Circ Physiol       Date:  2019-03-29       Impact factor: 4.733

6.  Nitric oxide inhibits the expression of AT1 receptors in neurons.

Authors:  Neeru M Sharma; Hong Zheng; Yi-Fan Li; Kaushik P Patel
Journal:  Am J Physiol Cell Physiol       Date:  2012-01-04       Impact factor: 4.249

Review 7.  Reactive oxygen species in the neuropathogenesis of hypertension.

Authors:  Jeffrey R Peterson; Ram V Sharma; Robin L Davisson
Journal:  Curr Hypertens Rep       Date:  2006-06       Impact factor: 5.369

8.  Regional expression of NAD(P)H oxidase and superoxide dismutase in the brain of rats with neurogenic hypertension.

Authors:  Yongli Bai; Bahman Jabbari; Shaohua Ye; Vito M Campese; Nosratola D Vaziri
Journal:  Am J Nephrol       Date:  2008-11-27       Impact factor: 3.754

Review 9.  Angiotensin-II, the Brain, and Hypertension: An Update.

Authors:  Colin N Young; Robin L Davisson
Journal:  Hypertension       Date:  2015-08-31       Impact factor: 10.190

Review 10.  Brain renin-angiotensin system dysfunction in hypertension: recent advances and perspectives.

Authors:  Shereeni J Veerasingham; Mohan K Raizada
Journal:  Br J Pharmacol       Date:  2003-05       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.